5 research outputs found
Synthesis of Polymer–Lipid Nanoparticles for Image-Guided Delivery of Dual Modality Therapy
For advanced treatment of diseases such as cancer, multicomponent, multifunctional nanoparticles hold great promise. In the current study we report the synthesis of a complex nanoparticle (NP) system with dual drug loading as well as diagnostic properties. To that aim we present a methodology where chemically modified poly(lactic-co-glycolic) acid (PLGA) polymer is formulated into a polymer-lipid NP that contains a cytotoxic drug doxorubicin (DOX) in the polymeric core and an anti-angiogenic drug sorafenib (SRF) in the lipidic corona. The NP core also contains gold nanocrystals (AuNCs) for imaging purposes and cyclodextrin molecules to maximize the DOX encapsulation in the NP core. In addition, a near-infrared (NIR) Cy7 dye was incorporated in the coating. To fabricate the NP we used a microfluidics-based technique that offers unique NP synthesis conditions, which allowed for encapsulation and fine-tuning of optimal ratios of all the NP components. NP phantoms could be visualized with computed tomography (CT) and near-infrared (NIR) fluorescence imaging. We observed timed release of the encapsulated drugs, with fast release of the corona drug SRF and delayed release of a core drug DOX. In tumor bearing mice intravenously administered NPs were found to accumulate at the tumor site by fluorescence imaging. © 2013 American Chemical Society
Recommended from our members
Synthesis of Polymer–Lipid Nanoparticles for Image-Guided Delivery of Dual Modality Therapy
For advanced treatment of diseases such as cancer, multi component, multi functional nanoparticles hold great promise. In the current study we report the synthesis of a complex nanoparticle (NP) system with dual drug loading as well as diagnostic properties. To that aim we present a methodology where chemically modified poly(lactic co glycolic) acid (PLGA) polymer is formulated into a polymer lipid NP that contains a cytotoxic drug doxorubicin (DOX) in the polymeric core and an anti angiogenic drug sorafenib (SRF) in the lipidic corona. The NP core also contains gold nanocrystals (AuNCs) for imaging purposes and cyclodextrin molecules to maximize the DOX encapsulation in the NP core. In addition, a near infrared (NIR) Cy7 dye was incorporated in the coating. To fabricate the NP we used a microfluidics based technique that offers unique NP synthesis conditions, which allowed for encapsulation and fine tuning of optimal ratios of all the NP components. NP phantoms could be visualized with computed tomography (CT) and near infrared (NIR) fluorescence imaging. We observed timed release of the encapsulated drugs, with fast release of the corona drug SRF and delayed release of a core drug DOX. In tumor bearing mice intravenously administered NPs were found to accumulate at the tumor site by fluorescence imaging
Synthesis of Polymer–Lipid Nanoparticles for Image-Guided Delivery of Dual Modality Therapy
For advanced treatment of diseases
such as cancer, multicomponent,
multifunctional nanoparticles hold great promise. In the current study
we report the synthesis of a complex nanoparticle (NP) system with
dual drug loading as well as diagnostic properties. To that aim we
present a methodology where chemically modified polyÂ(lactic-<i>co</i>-glycolic) acid (PLGA) polymer is formulated into a polymer–lipid
NP that contains a cytotoxic drug doxorubicin (DOX) in the polymeric
core and an anti-angiogenic drug sorafenib (SRF) in the lipidic corona.
The NP core also contains gold nanocrystals (AuNCs) for imaging purposes
and cyclodextrin molecules to maximize the DOX encapsulation in the
NP core. In addition, a near-infrared (NIR) Cy7 dye was incorporated
in the coating. To fabricate the NP we used a microfluidics-based
technique that offers unique NP synthesis conditions, which allowed
for encapsulation and fine-tuning of optimal ratios of all the NP
components. NP phantoms could be visualized with computed tomography
(CT) and near-infrared (NIR) fluorescence imaging. We observed timed
release of the encapsulated drugs, with fast release of the corona
drug SRF and delayed release of a core drug DOX. In tumor bearing
mice intravenously administered NPs were found to accumulate at the
tumor site by fluorescence imaging